Marina Udier Blagovic is a biotech CEO and Independent Board Director with extensive experience in the fields of cancer immunotherapy and advanced manufacturing. Currently, they lead Nouscom AG, a clinical-stage company focused on neoantigen-based therapies, where they have built a global team and advanced multiple clinical trials. Previously, they held pivotal roles at Novartis, overseeing the development of key oncology products and strategies. Marina has also contributed to venture capital as an Operating Principal at Versant Ventures and has served as a Board Member for Celyad Oncology. They hold a PhD in Organic Chemistry from Yale University and are passionate about translating scientific advancements into impactful therapies while fostering high-performing teams.